Eribulin mesylate

London, January 19, 2026 Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative programmes, announced that it has entered into a collaboration and licence agreement with Innolake Biopharm Co. Ltd (“Innolake”) to develop a clinical stage first-in-class antibody drug conjugate (ADC). Under the partnership, Ellipses gains rights to develop a B7H3 targeted ADC with an eribulin payload (ILB-3101) worldwide excluding greater China. ILB-3101 has the potential to treat multiple tumour types and to address resistance to topoisomerase-1 based ADCs. ILB-3101 is designated as EP0028 by Ellipses. Ellipses and Innolake will collaborate closely on the development of ILB-3101/EP0028, which is currently in a Phase 1 trial in China sponsored by Innolake. Ellipses will initiate a Phase 1 clinical trial in the US with expansion to Europe and other territories following relevant regulatory approvals. EP0028 is an important addition to Ellipses’ clinical-stage pipeline and is the second programme Ellipses has in-licensed from an innovative biotech company based in China. The first programme, EP0031, is a next-generation selective RET inhibitor developed by Kelun Biotech, which Ellipses is currently advancing through Phase 2 trials. Professor Sir Chris Evans, OBE, Executive Chair of Ellipses, commented: “We are delighted to bring this differentiated ADC into our pipeline. EP0028 has the potential to address unmet needs in a range of indications and further strengthens our strategy to develop Chinese originated assets in the West.” Professor Tobias Arkenau, Global Head of Drug Development and Chief Medical Officer of Ellipses, commented:“Ellipses’ decision to in-license EP0028 is a significant milestone for us in continuing our mission to develop new cancer drugs for patients with high unmet clinical needs. Our collaboration with Innolake is another great opportunity to develop innovative cancer drugs globally, robustly and at speed to serve our communities.” Mingde Xia, CEO of Innolake, commented:“This partnership is a great validation of our technology and capabilities. Having advanced ILB-3101 from early discovery through to the clinic, we are delighted to collaborate with Ellipses and look forward to bringing this innovative therapy to patients worldwide.” About Ellipses Ellipses is a global clinical-stage drug development company focused on progressing first- or best-in-class oncology drugs. Ellipses’ maturing clinical pipeline is progressing three clinical phase-2 programmes with an additional programme due to commence Phase 1 studies in 2026. Ellipses is supported by a global Scientific Advisory Group comprising over 300 leading Oncology Key Opinion Leaders to de-risk initial asset selection and provide critical insights into clinical trial design. www.ellipses.life About Innolake Innolake is a Hangzhou/Shanghai-based innovative clinical stage biotech company developing therapies to target unmet medical needs in cancer and autoimmune diseases. The company has leveraged its proprietary technology platforms and in-house R&D capabilities to generate a pipeline of ADCs/biologics and small molecule programmes. http://www.innolakebio.com Contacts Media@Ellipses.life Ramsay Smith, Media House International +44 (0)7788414856 ramsay@mediahouse.co.uk

BioNTech and partner Bristol Myers Squibb on Tuesday unveiled promising interim findings from a mid-stage study evaluating their investigational PD-L1xVEGF-A blocking bispecific antibody pumitamig (BNT327/BMS986545) in combination with chemotherapy to treat patients with locally advanced or metastatic triple-negative breast cancer (TNBC), irrespective of PD-L1 expression levels.After touting encouraging response data from an earlier Phase Ib/II trial in a treatment-naïve population at the San Antonio Breast Cancer Symposium (SABCS) last year, the partners — at this year’s meeting — reported further encouraging antitumour activity and a manageable safety profile for pumitamig across both first- and second-line treatment settings, laying the groundwork for the Phase III ROSETTA BREAST-01 trial.The Phase II study assessed two pumitamig regimens with chemotherapy: Cohort 1 received 15 or 20 mg/kg every two weeks with nab-paclitaxel, and Cohort 2 received a flat 20 mg/kg dose with either paclitaxel, gemcitabine plus carboplatin, or eribulin across three arms.Notable responsesThe interim analysis as of the October 1 cut-off included 74 patients with first- or second-line locally advanced/metastatic TNBC. Results showed that among 39 efficacy-evaluable patients in Cohort 1, the confirmed objective response rate (cORR) was 61.5%, whilst the unconfirmed ORR (uORR) was 71.8% and disease control rate was 92.3%. Additionally, responses proved consistent across PD-L1 expression levels, with an uORR of 70.6% observed in both combined positive score (CPS) ≥10 and CPS <10 subgroups.“The encouraging results are especially meaningful in patients with PD-L1 low or negative tumours…representing the potential of pumitamig…across PD-L1 expression levels, including patients who historically have had fewer effective treatments,” remarked Anne Kerber, head of development for haematology, oncology, cell therapy at BMS.The companies also noted higher pumitamig doses correlated with better responses, reaching 80.0% uORR at 20 mg/kg versus 63.2% at 15 mg/kg. In terms of lines of treatment, the uORRs were 76.5% and 68.2% in first- and second-line settings, respectively. Furthermore, the 9-month progression-free survival (PFS) rate was 59.3%, while median PFS, duration of response and overall survival were yet to mature at the time.Safety-wise, pumitamig’s profile was manageable, with Grade ≥3 treatment-related adverse events reported in 42.5% and 38.2% of patients in Cohorts 1 and 2, respectively, and no treatment-related deaths.Extensive development footprintBesides TNBC, the bispecific is being investigated in lung cancer indications as part of the pivotal ROSETTA clinical programme. Two mid-stage studies in extensive-stage small-cell lung cancer read out favourably this year — first in a Chinese population and second in a global one. Meanwhile, the asset is also being explored in non–small-cell lung cancer and mesothelioma (for more, see Spotlight On: Combos key to BioNTech’s PD-L1/VEGF bispecific strategy). “The activity we see in TNBC…further supports the pan-tumour potential of pumitamig, which we are advancing…in a broad development programme that also includes novel/novel combination regimens,” remarked Özlem Türeci, BioNTech’s chief medical officer.Interest in PD-(L)1/VEGF bispecifics started gaining traction last year when Akeso Biopharma and Summit Therapeutics indicated that ivonescimab could potentially unseat Merck & Co.’s Keytruda (pembrolizumab) in lung cancer. Merck soon responded, securing rights to LM-299 from LaNova Medicines in a $588-million upfront deal.